USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression

Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metab...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Biochimica et biophysica acta. General subjects Ročník 1869; číslo 9; s. 130830
Hlavní autori: Chen, Dejia, Zhao, Yue, Zhang, Xiaobo, Shi, Xiaocheng, Liu, Yiming, Lou, Ge
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Netherlands Elsevier B.V 01.08.2025
Predmet:
Apoptosis
C-Myc
Cell Line, Tumor
Cell Movement
Cell Proliferation
Deubiquitination
Disease Progression
Female
Gene Expression Regulation, Neoplastic
Glycolysis
Humans
Metabolic reprogramming
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
Protein Stability
Proto-Oncogene Proteins c-myc - genetics
Proto-Oncogene Proteins c-myc - metabolism
SP33
Ubiquitin Thiolesterase - genetics
Ubiquitin Thiolesterase - metabolism
C-Myc
Glycolysis
SP33
Metabolic reprogramming
Deubiquitination
Ovarian cancer
ISSN:0304-4165, 1872-8006, 1872-8006
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metabolic reprogramming. Here, we identify and characterize the function of the deubiquitinase USP33 in regulating c-Myc stability and glycolytic metabolism in OC. Through quantitative PCR (qPCR) and Western blot analyses, we show that USP33 is significantly upregulated in both OC tissues and cell lines compared to normal controls. Functional assays reveal that USP33 knockdown markedly inhibits cell proliferation, migration, and invasion while promoting apoptosis. Metabolically, USP33 silencing reduces glucose uptake, lactate production, and the extracellular acidification rate, consistent with downregulation of key glycolytic enzymes (LDHA, GLUT1, and PKM2). Mechanistically, co-immunoprecipitation and ubiquitination assays demonstrate that USP33 interacts with and deubiquitinates c-Myc at K48-linked chains, thereby stabilizing c-Myc protein levels and enhancing its transcriptional activity. Moreover, c-Myc overexpression rescues the inhibitory effects of USP33 knockdown on both glycolysis and malignant phenotypes. Clinically, high USP33 expression correlates with poor prognosis, suggesting that the USP33–c-Myc axis may serve as both a prognostic biomarker and a potential therapeutic target. Taken together, our findings highlight a critical role for USP33 in OC pathogenesis by mediating c-Myc-driven glycolytic reprogramming, and they provide new insights for developing targeted treatment strategies aimed at disrupting this pathway. •USP33 is upregulated in ovarian cancer: Significantly higher expression is observed in tumor tissues and cell lines compared to normal controls.•Promotes malignancy: USP33 knockdown inhibits proliferation, migration, and invasion while inducing apoptosis.•Enhances glycolysis: USP33 stabilizes c-Myc, upregulating glycolytic enzymes (LDHA, GLUT1, PKM2) to increase glycolytic flux.•Deubiquitinates c-Myc: Removes K48-linked ubiquitin chains, preventing degradation and enhancing transcriptional activity.•Clinical relevance: High USP33 levels predict poor prognosis, indicating USP33/c-Myc as a potential therapeutic and diagnostic target.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0304-4165
1872-8006
1872-8006
DOI:10.1016/j.bbagen.2025.130830